|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-4-14
|
|
pubmed:abstractText |
Damage of the blood-brain barrier and the migration of immunocompetent cells into the CNS represent key events in the immunopathogenesis of multiple sclerosis (MS). Cladribine is an immunosuppressive drug currently investigated in a phase-III clinical trial for relapsing-remitting MS. However, its precise mode of action remains elusive so far.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1468-1331
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
409-12
|
|
pubmed:meshHeading |
pubmed-meshheading:19175384-Adult,
pubmed-meshheading:19175384-Antigens, CD14,
pubmed-meshheading:19175384-Antigens, CD4,
pubmed-meshheading:19175384-Antigens, CD8,
pubmed-meshheading:19175384-Cell Movement,
pubmed-meshheading:19175384-Cladribine,
pubmed-meshheading:19175384-Flow Cytometry,
pubmed-meshheading:19175384-Humans,
pubmed-meshheading:19175384-Immunosuppressive Agents,
pubmed-meshheading:19175384-Leukocytes, Mononuclear,
pubmed-meshheading:19175384-Monocytes,
pubmed-meshheading:19175384-Multiple Sclerosis,
pubmed-meshheading:19175384-Phytohemagglutinins,
pubmed-meshheading:19175384-T-Lymphocytes
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
|
|
pubmed:affiliation |
Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine University, Düsseldorf, Germany.
|
|
pubmed:publicationType |
Journal Article
|
